| Gene symbol | S | Synonyms | E2 | Type of gene | protein-coding | |
| Chromosome | - | Map location | NC_004718.3 (21492..25259) | dbXrefs | Entrez:1489668 - | |
| Gene perturbation-related omics dataset | PerturbAtlas | |||||
| Description | spike glycoprotein | |||||
| GTO ID | GTC3365 |
| Trial ID | NCT05765578 |
| Disease | COVID-19 |
| Altered gene | S |
| Therapeutic/Target gene | Therapeutic gene |
| Therapy | mRNA vaccine |
| Treatment | Moderna COVID-19 Vaccine|mRNA-1273.222|Pfizer COVID-19 Vaccine|BNT162b2 bivalent booster|Moderna 2023 Updated COVID-19 Vaccine|XBB.1.5|Pfizer 2023 Updated COVID-19 Vaccine|XBB.1.5 |
| Location approved | US, Canada, Israel, EU, Switzerland, Singapore, Qatar, Vietnam, UK, Philippines, Thailand, Japan, South Korea, Brunei, Paraguay, China, Botswana, India, Indonesia, Saudi Arabia, Mexico, Australia, Nigeria, Colombia |
| Recruitment status | Active, Not Recruiting |
| Title | DisCOVEries 2 - An Observational Study to Evaluate the Immunogenicity of mRNA COVID-19 Bivalent Vaccines (Original and Omicron BA.4/BA.5) and 2023 Updated mRNA COVID-19 Vaccines (XBB.1.5) |
| Year | 2023 |
| Country | United States |
| Company sponsor | ModernaTX, Inc. |
| Other ID(s) | mRNA-1273-P922 |
| Vector information | |||
|
|||
| Cohort1: Moderna COVID-19 Vaccine | |||||
|
|||||
| Cohort2: Pfizer COVID-19 Vaccine | |||||
|
|||||
| Cohort3: Moderna 2023 Updated COVID-19 vaccine (XBB.1.5) | |||||
|
|||||
| Cohort4: Pfizer 2023 Updated COVID-19 vaccine (XBB.1.5) | |||||
|
|||||